Specialty Pharma Journal Specialty, Precision & Technology
NEW YORK & SAN DIEGO–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) and Illumina, Inc. (NASDAQ: ILMN) today announced a collaboration that will utilize Illumina’s next-generation sequencing (NGS) technology to develop and globally commercialize in-vitro diagnostic (IVD) assays in support of Bristol-Myers Squibb’s oncology portfolio. The companies plan to develop a diagnostic version of the Illumina …
Tag Archives: Bristol-Myers Squib
April, 2018
May, 2016
-
18 May
FDA Grants Accelerated Approval to BMS’ Opdivo for Classical Hodgkin Lymphoma
PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has approved Opdivo®(nivolumab) for the treatment of patients with classical Hodgkin lymphoma (cHL) who have relapsed or progressed after autologous hematopoietic stem cell transplantation (auto-HSCT) and post-transplantation brentuximab vedotin.1 This accelerated approval is based on …
October, 2015
-
29 October
FDA Expands Approval of BMS’ Yervoy in Melanoma
PRINCETON, N.J., Oct 28, 2015 (BUSINESS WIRE) — Bristol-Myers Squibb Company BMY, +0.60% today announced that the U.S. Food and Drug Administration (FDA) has approved Yervoy (ipilimumab) 10 mg/kg for the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm …